



**EXHIBIT B**  
**MARKED UP COPY OF THE AMENDED CLAIMS**  
**U.S. PATENT APPLICATION NO. 09/823,307**  
**ATTORNEY DOCKET NO. 7853-235-999**

**RECEIVED**  
**AUG 26 2002**  
**TECH CENTER 1600/2900**

21. (Amended) A method of [modulating] inhibiting costimulation of human T lymphocytes comprising: contacting a human T lymphocyte with [an 8F4 modulator selected from the group consisting of an 8F4 polypeptide and] a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

- a) is an inducible T cell costimulatory molecule;
- b) occurs on two-signal-activated human T lymphocytes;
- c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
- d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE, such that costimulation of the human T lymphocyte is modulated.

25. (Amended) The method of claim [23 or 24] 21, wherein the monoclonal antibody recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.

26. (Amended) The method of claim [23 or 24] 21, wherein the monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.

27. (Amended) The method of claim [23 or 24] 21, wherein the monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.

28. (Amended) The method of claim [23 or 24] 21, wherein the monoclonal antibody recognizes a human 8F4 polypeptide present on activated human CD4<sup>+</sup> T lymphocytes and activated human CD8<sup>+</sup> T lymphocytes.

30. (Amended) A method of inhibiting rejection of an organ transplant, comprising: administering to an individual in need of such inhibition an 8F4 inhibitory molecule [selected from the group consisting of an 8F4 polypeptide and], which 8F4 inhibitory molecule is a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

- a) is an inducible T cell costimulatory molecule;
- b) occurs on two-signal-activated human T lymphocytes;
- c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
- d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE, in an amount sufficient to inhibit rejection of an organ transplant.

32. (Amended) The method of claim [31] 30, wherein the monoclonal antibody recognizes the human 8F4 polypeptide of about 55 kilodaltons to 60 kilodaltons, as determined by non-reducing SDS-PAGE.

33. (Amended) The method of claim [31] 30, wherein the monoclonal antibody recognizes the peptide chain of about 27 kilodaltons, as determined by reducing SDS-PAGE.

34. (Amended) The method of claim [31] 30, wherein the monoclonal antibody recognizes the peptide chain of about 29 kilodaltons, as determined by reducing SDS-PAGE.

35. (Amended) The method of claim [31] 30, wherein the monoclonal antibody recognizes a human 8F4 polypeptide present on activated human CD4<sup>+</sup> T lymphocytes and activated human CD8<sup>+</sup> T lymphocytes.